Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Prasanth Nuthakki

Interventional Pain Medicine Munster, IN Medical Doctor

NPI 1114046455 CMS profile 322939

701 Superior Ave Ste B, Ste B, Munster, IN 46321

Open in the dashboard

General payments

$6,819

184 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Prasanth Nuthakki of Munster, IN is reported in the CMS Open Payments database as having received $6,819 across 184 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $553 21
2024 General $532 15
2023 General $1,205 19
2022 General $917 18
2021 General $733 28
2020 General $1,238 31
2019 General $1,642 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Prasanth Nuthakki
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Prasanth Nuthakki were reported at $553. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Prasanth Nuthakki Interventional Pain Medicine median Middle half National median
2019 $1,642 $684 $216–$2,079 $163
2020 $1,238 $382 $122–$1,109 $114
2021 $733 $552 $167–$1,554 $132
2022 $917 $605 $187–$1,924 $149
2023 $1,205 $671 $195–$1,915 $160
2024 $532 $684 $206–$1,837 $164
2025 $553 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,719 67 payments
  2. Abbott Laboratories $1,105 26 payments
  3. Medtronic USA, Inc. $1,079 30 payments
  4. Boston Scientific Corporation $459 7 payments
  5. Painteq LLC $296 3 payments
  6. Pacira Pharmaceuticals Incorporated $212 1 payment
  7. Stimwave Technologies Incorporated $180 1 payment
  8. Horizon Therapeutics plc $120 6 payments
  9. Nevro Corp. $80 4 payments
  10. Flexion Therapeutics, Inc. $79 5 payments
  11. Other $489 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,245 180 payments
  2. Consulting Fee $362 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $212 1 payment
Products named General payments · program years 2019–2025
  1. Accurian $817 16 payments
  2. INTELLIS ADAPTIVESTIM $760 15 payments
  3. Proclaim Family of SCS IPGs $692 21 payments
  4. MYSTIM $579 18 payments
  5. VANTA ADAPTIVESTIM $486 8 payments
  6. General - Therapies $325 1 payment
  7. PAINTEQ $296 3 payments
  8. PROCLAIM $259 4 payments
  9. INTELLIS Spinal Cord Neurostimulation $255 5 payments
  10. INTELLIS Spinal Cord Neurostimulation $239 2 payments
  11. Other $1,930 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,779

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$49,950

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

21.8%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 23 $19,393
Buprenorphine Generic 25 $5,373
Celecoxib Generic 161 $4,098
Gabapentin Generic 322 $4,002
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 174 $3,336
Pregabalin Generic 125 $3,000
Lidocaine Generic 19 $2,790
Tramadol Hcl-Acetaminophen Tramadol Hcl/Acetaminophen Brand 79 $1,427
Tramadol Hcl Generic 200 $1,154
Tizanidine Hcl Generic 118 $1,057

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$135,272

Medicare's payments for the services billed

Medicare patients

416

Average age 74

Services billed

2,044

279 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 35%
Ischemic heart disease 32%
Depression 31%
Chronic kidney disease 27%
COPD 27%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

184 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record